Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis

A. Blauvelt; K. Reich; R. B. Warren; J. C. Szepietowski; B. Sigurgeirsson; S. K. Tyring; I. Messina; V. Bhosekar; J. Oliver; C. Papavassilis; J. Frueh; R. G.B. Langley

doi:10.1111/bjd.15656

Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis

A. Blauvelt, K. Reich, R. B. Warren, J. C. Szepietowski, B. Sigurgeirsson, S. K. Tyring, I. Messina, V. Bhosekar, J. Oliver, C. Papavassilis, J. Frueh, R. G.B. Langley^*

^*Corresponding author for this work

Faculty of Medicine

University of Iceland, Iceland

Research output: Contribution to journal › Letter › peer-review

16 Citations (Scopus)

Original language	English
Pages (from-to)	879-881
Number of pages	3
Journal	British Journal of Dermatology
Volume	177
Issue number	3
DOIs	https://doi.org/10.1111/bjd.15656
Publication status	Published - Sept 2017

Access to Document

10.1111/bjd.15656

Cite this

Blauvelt, A., Reich, K., Warren, R. B., Szepietowski, J. C., Sigurgeirsson, B., Tyring, S. K., Messina, I., Bhosekar, V., Oliver, J., Papavassilis, C., Frueh, J., & Langley, R. G. B. (2017). Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. British Journal of Dermatology, 177(3), 879-881. https://doi.org/10.1111/bjd.15656

@article{a8feff37f3d140d3859d2581787eaee0,

title = "Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis",

author = "A. Blauvelt and K. Reich and Warren, {R. B.} and Szepietowski, {J. C.} and B. Sigurgeirsson and Tyring, {S. K.} and I. Messina and V. Bhosekar and J. Oliver and C. Papavassilis and J. Frueh and Langley, {R. G.B.}",

note = "Funding Information: The authors received writing and editorial support from Andrew Horgan, PhD (BioScience Communications, New York, NY), which was supported by Novartis.",

year = "2017",

month = sep,

doi = "10.1111/bjd.15656",

language = "English",

volume = "177",

pages = "879--881",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Oxford University Press",

number = "3",

}

Blauvelt, A, Reich, K, Warren, RB, Szepietowski, JC, Sigurgeirsson, B, Tyring, SK, Messina, I, Bhosekar, V, Oliver, J, Papavassilis, C, Frueh, J & Langley, RGB 2017, 'Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis', British Journal of Dermatology, vol. 177, no. 3, pp. 879-881. https://doi.org/10.1111/bjd.15656

TY - JOUR

T1 - Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis

AU - Blauvelt, A.

AU - Reich, K.

AU - Warren, R. B.

AU - Szepietowski, J. C.

AU - Sigurgeirsson, B.

AU - Tyring, S. K.

AU - Messina, I.

AU - Bhosekar, V.

AU - Oliver, J.

AU - Papavassilis, C.

AU - Frueh, J.

AU - Langley, R. G.B.

N1 - Funding Information: The authors received writing and editorial support from Andrew Horgan, PhD (BioScience Communications, New York, NY), which was supported by Novartis.

PY - 2017/9

Y1 - 2017/9

UR - http://www.scopus.com/inward/record.url?scp=85029675242&partnerID=8YFLogxK

U2 - 10.1111/bjd.15656

DO - 10.1111/bjd.15656

M3 - Letter

C2 - 28498514

AN - SCOPUS:85029675242

SN - 0007-0963

VL - 177

SP - 879

EP - 881

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 3

ER -